1.Successful Management of Recurrent Colon Ulcer in Hemodialysis Patient after Conversion to Peritoneal Dialysis.
Ji Young LEE ; In Tae MOON ; Hye Young LEE ; Hang Lak LEE ; Dong Soo HAN
The Korean Journal of Gastroenterology 2015;66(6):350-353
Lower gastrointestinal complications often develop in end stage renal disease patients, and among the more problematic is recurrent colon ulcer. The exact pathogenesis of this condition is not known and there were no specific therapeutic modalities concerning this type of disease entity. We report, with a literature review, a case of recurrent colon ulcer with intermittent hematochezia in an end stage renal disease patient on long term hemodialysis that improved after conversion to peritoneal dialysis.
Aspirin/therapeutic use
;
Colon/pathology
;
Colonic Diseases/complications/*diagnosis/drug therapy
;
Colonoscopy
;
Drug Therapy, Combination
;
Gastrointestinal Hemorrhage
;
Humans
;
Kidney Failure, Chronic/*complications
;
Male
;
Middle Aged
;
Peritoneal Dialysis
;
Recurrence
;
Ticlopidine/therapeutic use
;
Ulcer/complications/*diagnosis/drug therapy
2.A case of a 13-year old girl with Sagliker syndrome.
Jishi LIU ; Ying JI ; Hua LUO ; Li WU ; Wei ZHANG ; Hao ZHANG
Chinese Journal of Pediatrics 2014;52(8):634-635
3.Intestinal Paragonimiasis with Colonic Ulcer and Hematochezia in An Elderly Taiwanese Woman.
Chung Te LIU ; Yen Cheng CHEN ; Tso Hsiao CHEN ; Ursula BARGHOUTH ; Chia Kwung FAN
The Korean Journal of Parasitology 2012;50(4):349-352
A 94-year-old female with end-stage renal disease presents with fever, fatigue, and hematochezia. She had previously resided in Hunan Province, China, and Myanmar, and she immigrated to Taiwan 30 years ago. Colonoscopy revealed a colonic ulcer. Biopsy of the colonic ulcer showed ulceration of the colonic mucosa, and many Paragonimus westermani-like eggs were noted. Serum IgG antibody levels showed strong reactivity with P. westermani excretory-secretory antigens by ELISA. Intestinal paragonimiasis was thus diagnosed according to the morphology of the eggs and serologic finding. After treatment with praziquantel, hematochezia resolved. The present case illustrates the extreme manifestations encountered in severe intestinal paragonimiasis.
Aged, 80 and over
;
Animals
;
Anthelmintics/therapeutic use
;
Antibodies, Helminth/blood
;
Antigens, Helminth/immunology
;
Colonic Diseases/complications/drug therapy/*pathology
;
Colonoscopy
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Gastrointestinal Hemorrhage/complications/drug therapy/*pathology
;
Humans
;
Intestinal Diseases, Parasitic/complications/drug therapy/parasitology/*pathology
;
Kidney Failure, Chronic/complications
;
Paragonimiasis/complications/drug therapy/parasitology/*pathology
;
Paragonimus westermani/*immunology
;
Praziquantel/therapeutic use
;
Taiwan
;
Ulcer/complications/drug therapy/*pathology
4.Interstitial Pneumonitis in a Patient with Chronic Hepatitis C and Chronic Renal Failure on Interferon Therapy.
Eun Jung KANG ; Dong Kyun KIM ; Seong Ran JEON ; Hyun Sook CHOI ; Soung Won JEONG ; Jae Young JANG ; Joon Seong LEE ; Soo Taek UH
The Korean Journal of Gastroenterology 2011;58(1):47-52
After 4-months of alpha interferon (IFN-alpha), a 64-year old woman with chronic hepatitis C developed a cough and dyspnea and showed diffuse infiltrative opacities on her chest X-ray. Her symptoms persisted after stopping the IFN-alpha therapy. Pulmonary function testing revealed a reduced forced vital capacity. High-resolution computed tomography of the lung showed peripheral and peribronchovascular ground glass attenuation and consolidation associated with reticulation. Bronchoalveolar lavage was performed for further evaluation and showed a lymphocyte level of 8.2%, an uncommon finding in IFN-alpha-induced interstitial pneumonitis. We performed a lung biopsy to diagnose her disease and it suggested interstitial pneumonitis. This was considered to be due to the immunomodulatory effects of INF-alpha. Although rare, any sign of significant pulmonary involvement should be evaluated.
Antiviral Agents/*adverse effects/therapeutic use
;
Bronchoalveolar Lavage
;
Female
;
Hepatitis C, Chronic/complications/*drug therapy
;
Humans
;
Interferon-alpha/*adverse effects/therapeutic use
;
Kidney Failure, Chronic/complications
;
Lung Diseases, Interstitial/*chemically induced/pathology/radiography
;
Middle Aged
;
Respiratory Function Tests
;
Tomography, X-Ray Computed
5.Calcium Polystyrene Sulfonate Induced Colonic Necrosis in Patient with Chronic Kidney Disease.
Sung Hoa LEE ; Sung Jung KIM ; Go Eun KIM ; Woo Jin LEE ; Won Ki HONG ; Gwang Ho BAIK ; Young Hee CHOI ; Dong Joon KIM
The Korean Journal of Gastroenterology 2010;55(4):261-265
A 63-year-old woman was admitted due to right upper quadrant abdominal pain. She was going through hemodialysis due to end stage renal disease and taking calcium polystyrene sulfonate orally and rectally due to hyperkalemia. Colonoscopy showed a circular ulcerative mass on the proximal ascending colon. Biopsy specimen from the mass showed inflammation and necrotic debris. It also revealed basophilic angulated crystals which were adherent to the ulcer bed and normal mucosa. These crystals were morphologically consistent with calcium polystyrene sulfonate. She was diagnosed with calcium polystyrene phosphate induced colonic necrosis and improved with conservative treatment.
Colonic Diseases/chemically induced/complications/*pathology
;
Colonoscopy
;
Female
;
Humans
;
Kidney Failure, Chronic/complications/*diagnosis
;
Middle Aged
;
Necrosis
;
Polystyrenes/*adverse effects
6.Improvement in Erythropoieis-stimulating Agent-induced Pure Red-cell Aplasia by Introduction of Darbepoetin-alpha When the Anti-erythropoietin Antibody Titer Declines Spontaneously.
Hajeong LEE ; Jaeseok YANG ; Hyosang KIM ; Ju Won KWON ; Kook Hwan OH ; Kwon Wook JOO ; Yon Su KIM ; Curie AHN ; Jin Suk HAN ; Suhnggwon KIM
Journal of Korean Medical Science 2010;25(11):1676-1679
Anti-erythropoietin antibodies usually cross-react with all kinds of recombinant erythropoietins; therefore, erythropoiesis-stimulating agent (ESA)-induced pure red-cell aplasia (PRCA) is not rescued by different ESAs. Here, we present a case of ESA-induced PRCA in a 36-yr-old woman with chronic kidney disease, whose anemic condition improved following reintroduction of darbepoetin-alpha. The patient developed progressive, severe anemia after the use of erythropoietin-alpha. As the anemia did not improve after the administration of either other erythropoietin-alpha products or erythropoietin-beta, all ESAs were discontinued. Oxymetholone therapy failed to improve the transfusion-dependent anemia and a rechallenge with ESAs continuously failed to obtain a sustained response. However, her anemia improved following reintroduction of darbepoetin-alpha at 3 yr after the initial diagnosis. Interestingly, anti-erythropoietin antibodies were still detectable, although their concentration was too low for titration. In conclusion, darbepoetin-alpha can improve ESA-induced PRCA when the anti-erythropoietin antibody titer declines and its neutralizing capacity is lost.
Adult
;
Anemia/drug therapy/etiology
;
Antibodies/*blood/immunology
;
Bone Marrow Cells/pathology
;
Drug Hypersensitivity/immunology
;
Erythropoietin/*analogs & derivatives/therapeutic use
;
Erythropoietin, Recombinant/adverse effects/*immunology/therapeutic use
;
Female
;
Glomerulonephritis, IGA/complications
;
Hematinics/adverse effects/immunology/*therapeutic use
;
Humans
;
Kidney Failure, Chronic/complications
;
Oxymetholone/therapeutic use
;
Red-Cell Aplasia, Pure/chemically induced/*drug therapy/immunology
7.The Impact of the Aortic Pulse Wave Velocity on the Cardiovascular Outcomes of Hemodialysis Patients.
Seok Joon SHIN ; Yong Kyun KIM ; Sungjin CHUNG ; Hyun Wha CHUNG ; Sang Hyun IHM ; Cheol Whee PARK ; Young Ok KIM ; Ho Cheol SONG ; Yong Soo KIM ; Eui Jin CHOI
Journal of Korean Medical Science 2009;24(Suppl 1):S121-S128
The aims of our study were to identify the risk factors for an increased aortic pulse wave velocity (AoPWV) and to assess the impact of the AoPWV on the cerebro-cardiovascular (CV) outcomes of hemodialysis (HD) patients. Seventy two HD patients were included, and the AoPWV, the echocardiography and the biochemical parameters were measured. After dividing the patients into tertiles according to the AoPWV values, we defined the low, the middle and the high AoPWV groups. The patients in the high AoPWV group showed a significantly higher age and high-sensitivity C-reactive protein level, a greater prevalence of diabetes and statin use, left ventricular hypertrophy, average pulse pressure (PP), AoPWV and left ventricular mass index and a lower serum albumin level than those in the low AoPWV group (p<0.05). On multivariate regression analysis of the AoPWV, age and the average PP were independently related to the AoPWV (p<0.05). On the multivariate Cox analysis for CV outcomes, the AoPWV and the average PP remained significant independent predictors of CV events. Our data suggest that an increased AoPWV is an independent predictor for the CV outcomes of HD patients.
Adult
;
Aged
;
Albumins/metabolism
;
Aorta/*pathology
;
C-Reactive Protein/metabolism
;
Echocardiography/methods
;
Female
;
Heart Rate
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
;
Kidney Failure, Chronic/*complications/*therapy
;
Male
;
Middle Aged
;
*Pulse
;
Renal Dialysis/methods
8.N-terminal Pro-Brain Natriuretic Peptide Levels Predict Left Ventricular Systolic Function in Patients with Chronic Kidney Disease.
Jung Eun LEE ; So Yeon CHOI ; Wooseong HUH ; Seong Woo PARK ; Dae Joong KIM ; Ha Young OH ; Yoon Goo KIM
Journal of Korean Medical Science 2009;24(Suppl 1):S63-S68
N-terminal pro-brain natriuretic peptide (NT-proBNP) can be a useful marker for left ventricular (LV) dysfunction in patients without kidney disease. This study was conducted to clarify the relationship between NT-proBNP and LV systolic function in patients with decreased renal function. We studied 256 chronic kidney disease (CKD) patients, patients on dialysis were excluded. The median glomerular filtration rate was 24 (13-36) mL/min/1.73 m(2) and the median NT-proBNP was 4,849 (1,310- 19,009) pg/mL. The prevalence of LV systolic dysfunction increased from the lower to the upper NT-proBNP quartiles (I, 17%; II, 34%; III, 61%; and IV, 72%; p<0.001 for trend). The NT-proBNP quartile was an independent predictor of LV systolic dysfunction after adjustment for renal function, compared with quartile I: II, odds ratio (OR) 3.99 (95% confidence interval [CI],1.34-11.93); III, OR 11.28 (95% CI, 3.74-33.95); and IV, OR 36.97 (95% CI, 11.47-119.1). Area under the curve and optimum cut points for NT-proBNP to detect LV systolic dysfunction were 0.781 and 2,165 pg/mL in CKD stage 3, 0.812 and 4,740 pg/mL in CKD stage 4, and 0.745 and 15,892 pg/ mL in CKD stage 5. The NT-proBNP level was a predictor of LV systolic dysfunction in CKD patients. Optimum cut points should be stratified according to renal function.
Aged
;
Area Under Curve
;
Female
;
Glomerular Filtration Rate
;
Humans
;
Kidney Failure, Chronic/*complications/pathology
;
Male
;
Middle Aged
;
Natriuretic Peptide, Brain/*blood
;
Peptide Fragments/diagnostic use
;
Prevalence
;
Protein Structure, Tertiary
;
Sensitivity and Specificity
;
Ventricular Dysfunction, Left/complications/diagnosis
;
*Ventricular Function, Left
9.A Case of a Patient with Both Chorea and Restless Legs Syndrome.
Yoon Kyung SHIN ; Seung Chul HONG ; Yon Kwon IHN ; Jong Hyun JEONG ; Jin Hee HAN ; Sung Pil LEE
Journal of Korean Medical Science 2008;23(3):533-536
The patient was a 44-yr-old man with end-stage renal disease who had developed chorea as a result of hypoglycemic injury to the basal ganglia and thalamus and who was subsequently diagnosed with depression and restless legs syndrome (RLS). For proper management, the presence of a complex medical condition including two contrasting diseases, chorea and RLS, had to be considered. Tramadol improved the pain and dysesthetic restlessness in his feet and legs, and this was gradually followed by improvements in his depressed mood, insomnia, lethargy, and feelings of hopelessness. This case suggests that the dopaminergic system participates intricately with the opioid, serotoninergic, and noradrenergic systems in the pathophysiology of RLS and pain and indirectly of depression and insomnia.
Adult
;
Analgesics, Opioid/therapeutic use
;
Anti-Dyskinesia Agents/therapeutic use
;
Chorea/*complications/pathology
;
Citalopram/therapeutic use
;
Drug Therapy, Combination
;
Haloperidol/therapeutic use
;
Humans
;
Kidney Failure, Chronic/*complications
;
Magnetic Resonance Imaging
;
Male
;
Restless Legs Syndrome/*complications/drug therapy/pathology
;
Serotonin Uptake Inhibitors/therapeutic use
;
Tramadol/therapeutic use
10.A case of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis.
Jae Young YOON ; Sun Yang MIN ; Ju Yee PARK ; Seung Goun HONG ; Sang Jong PARK ; So Ya PAIK ; Young Min PARK
The Korean Journal of Hepatology 2008;14(1):97-101
Allopurinol-induced hypersensitivity syndrome is characterized by an idiosyncratic reaction involving multiple-organs, which usually begins 2 to 6 weeks after starting allopurinol. In rare cases, the adverse reactions to allopurinol are accompanied by a variety of liver injury, such as reactive hepatitis, granulomatous hepatitis, vanishing bile duct syndrome, or fulminant hepatic failure. Here we report a case with granulomatous hepatitis and ductopenia. A 69-year-old man with chronic renal failure, hyperuricemia, and previously normal liver function presented with jaundice, skin rash, and fever 2 weeks after taking allopurinol (200 mg/day). In histopathology, a liver biopsy specimen showed mild spotty necrosis of hepatocytes, marked cholestasis in parenchyma, and some granulomas in the portal area. There were vacuolar degeneration in the interlobular bile ducts and ductopenia in the portal tracts. Pathologic criteria strongly suggested the presence of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis. The patient fully recovered following the early administration of systemic corticosteroid therapy.
Aged
;
Allopurinol/*adverse effects/therapeutic use
;
Antimetabolites/*adverse effects/therapeutic use
;
Bile Duct Diseases/*chemically induced/diagnosis/pathology
;
Bile Ducts, Intrahepatic/*drug effects/pathology
;
Cholestasis/*chemically induced/diagnosis/pathology
;
Drug Eruptions/pathology
;
Granuloma/*chemically induced/pathology
;
Hepatitis, Toxic/*pathology
;
Humans
;
Kidney Failure, Chronic/complications/drug therapy
;
Male

Result Analysis
Print
Save
E-mail